The first patient visit for Lilly’s five-year clinical trial assessing the company’s type-2 diabetes and weight-loss drug tirzepatide has taken place. 

The SURMOUNT-REAL UK trial will last for five years and will assess the long-term effectiveness of tirzepatide on obesity outcomes when given in primary care settings. Taking place in Greater Manchester, the trial aims to enroll up to 3,000 participants in the region.  

The trial will evaluate tirzepatide’s effects on weight reduction and its potential to delay progression to type 2 diabetes. It will also assess impacts on obesity-related complications and broader measures of health and healthcare use, including GP, hospital and A&E visits, work productivity, employment status and health-related quality of life. 

Lilly has partnered with several organisations across the North West of England to deliver the trial including North West EHealth, the University of Manchester and Health Innovation Manchester.   

 Professor Rachel Batterham, Senior Vice President for International Medical Affairs at Lilly, said: “Obesity is a pressing health challenge both in the UK and globally. Lilly is committed to working with partners across the health system to better understand and address its complexity. With SURMOUNT-REAL UK, we aim to generate real-world evidence on the long-term health impacts of obesity management medications—evidence that can help shape future care pathways and improve health outcomes for people living with obesity.” 

Professor Martin Rutter, Professor of Cardiometabolic Medicine at the University of Manchester and Chief Investigator for the trial, added: “In addition to endpoints assessing weight reduction and progression to type 2 diabetes, SURMOUNT-REAL UK will assess the broader health and healthcare impacts in a diverse group of individuals living across Greater Manchester. The trial is particularly important because it will contribute to the evidence base on intervening comparatively early in the progression of obesity. It’s fantastic that Greater Manchester was selected for the trial because of the excellent research infrastructure and the availability of primary care data for research across the region.”